The study was designed to evaluate the therapeutic and side effects of Bevacizumab plus FOLFIRI regimen as front-line therapy for Chinese patients with advanced colorectal cancer. A total of 15 previously untreated pa...The study was designed to evaluate the therapeutic and side effects of Bevacizumab plus FOLFIRI regimen as front-line therapy for Chinese patients with advanced colorectal cancer. A total of 15 previously untreated patients with advanced colorectal cancer received Bevacizumab plus FOLFIRI regimen as font-line therapy, in detail, irinotecan 180 mg/m2 was given intravenously on day1, then calcium folinate (CF) 200 mg/m2, F-fluorouracil (5-Fu) 400 mg/m2 given in bolus immediately after CF, day 1 - 2;5-Fu 600 mg/2 given continuously after bolus for 22 hours on day1, day2;Bevacizumab was given intravenously at dosage of 5 mg/kg, on day-1. Therapeutic and side effects were evaluated at least after four cycles of treatment. The results showed that all the cases among the group were valid for response evaluation, with CR 0, PR 10, SD 3, and PD 2. The response rate is 66.7% and median time to progression (mTTP) was 10.6 months. The main toxicities were bone marrow suppression, nausea and vomiting, stomach pain and diarrhea;there was no chemotherapy-related death. The data suggested that the combination regimen with Bevacizumab plus FOLFIRI regimen was effective as front-line therapy for Chinese patients with advanced colorectal cancer, and the side effects were tolerable and manageable.展开更多
AIM:To evaluate the efficacy and safety of paclitaxelnedaplatin combination as a front-line regimen in Chinese patients with metastatic esophageal squamous cell carcinoma(ESCC).METHODS:A two-center,open-label,single-a...AIM:To evaluate the efficacy and safety of paclitaxelnedaplatin combination as a front-line regimen in Chinese patients with metastatic esophageal squamous cell carcinoma(ESCC).METHODS:A two-center,open-label,single-arm phaseⅡstudy was designed.Thirty-nine patients were enrolled and included in the intention-to-treat analysis of efficacy and adverse events.Patients received 175mg/m2of paclitaxel over a 3 h infusion on 1 d,followed by nedaplatin 80 mg/m2in a 1 h infusion on 2 d every3 wk until the documented disease progression,unac-ceptable toxicity or patient’s refusal.RESULTS:Of the 36 patients assessable for efficacy,there were 2 patients(5.1%)with complete response and 16 patients(41.0%)with partial response,giving an overall response rate of 46.1%.The median progression-free survival and median overall survival for all patients were 7.1 mo(95%CI:4.6-9.7)and 12.4 mo(95%CI:9.5-15.3),respectively.Toxicities were moderate and manageable.Grade 3/4 toxicities included neutropenia(15.4%),nausea(10.3%),anemia(7.7%),thrombocytopenia(5.1%),vomiting(5.1%)and neutropenia fever(2.6%).CONCLUSION:The combination of paclitaxel and nedaplatin is active and well tolerated as a first-line therapy for patients with metastatic ESCC.展开更多
With insight from the methodology of phenomenology,Jan Patocka draws multiple meanings from the special front-line experience,including new understanding of the fringe of death,absolute freedom,universal responsibilit...With insight from the methodology of phenomenology,Jan Patocka draws multiple meanings from the special front-line experience,including new understanding of the fringe of death,absolute freedom,universal responsibility,and solidarity with enemies.The front-line experience is in sharp contrast with daily life experience,and is regarded by Patocka as a continuous consciousness of problematization toward history.This consciousness,which the front-line experience gives rise to,can be maintained through true care for reality and history.Patocka names this"care for the soul"and regards it as the core of the European spirit.The potential philosophical and historical value of the front-line experience urges Patocka to maintain an eternal fight,and he eventually concludes thatitis this eternal fight that brings forth eternal peace.展开更多
损伤控制(damage control,DC)理念历经30多年的发展,其内核已实现从损伤控制外科(damage control surgery,DCS)的单纯技术概念,向损伤控制复苏(damage control resuscitation,DCR)的生理管理理念演进。纵向上,损伤控制贯穿了从受伤点急...损伤控制(damage control,DC)理念历经30多年的发展,其内核已实现从损伤控制外科(damage control surgery,DCS)的单纯技术概念,向损伤控制复苏(damage control resuscitation,DCR)的生理管理理念演进。纵向上,损伤控制贯穿了从受伤点急救到确定性治疗的全过程;横向上,损伤控制跨越了病理生理学、多系统外科学、介入影像学等多个学科,并可应用于平时和战时双场景,其内涵和外延的不断演进推动了损伤控制医学(damage control medicine,DCM)作为一个系统性理论体系的发展。本文系统回顾了损伤控制的发展背景、发展历程和最新进展,以战场救护中“白金十分钟”“黄金一小时”“关键三小时”时效救治作为框架,与损伤控制急救(damage control emergency,DCE)、DCR、DCS相对应,探讨构建以3D为核心的DCM理论架构,并提出我军的损伤控制体系建设参考路径。展开更多
文摘The study was designed to evaluate the therapeutic and side effects of Bevacizumab plus FOLFIRI regimen as front-line therapy for Chinese patients with advanced colorectal cancer. A total of 15 previously untreated patients with advanced colorectal cancer received Bevacizumab plus FOLFIRI regimen as font-line therapy, in detail, irinotecan 180 mg/m2 was given intravenously on day1, then calcium folinate (CF) 200 mg/m2, F-fluorouracil (5-Fu) 400 mg/m2 given in bolus immediately after CF, day 1 - 2;5-Fu 600 mg/2 given continuously after bolus for 22 hours on day1, day2;Bevacizumab was given intravenously at dosage of 5 mg/kg, on day-1. Therapeutic and side effects were evaluated at least after four cycles of treatment. The results showed that all the cases among the group were valid for response evaluation, with CR 0, PR 10, SD 3, and PD 2. The response rate is 66.7% and median time to progression (mTTP) was 10.6 months. The main toxicities were bone marrow suppression, nausea and vomiting, stomach pain and diarrhea;there was no chemotherapy-related death. The data suggested that the combination regimen with Bevacizumab plus FOLFIRI regimen was effective as front-line therapy for Chinese patients with advanced colorectal cancer, and the side effects were tolerable and manageable.
基金Supported by Natural Science Foundation of Anhui Province No.070413256XMedical Research Foundation of Anhui Provincial Health Department No.2010B001 and No.13zc012
文摘AIM:To evaluate the efficacy and safety of paclitaxelnedaplatin combination as a front-line regimen in Chinese patients with metastatic esophageal squamous cell carcinoma(ESCC).METHODS:A two-center,open-label,single-arm phaseⅡstudy was designed.Thirty-nine patients were enrolled and included in the intention-to-treat analysis of efficacy and adverse events.Patients received 175mg/m2of paclitaxel over a 3 h infusion on 1 d,followed by nedaplatin 80 mg/m2in a 1 h infusion on 2 d every3 wk until the documented disease progression,unac-ceptable toxicity or patient’s refusal.RESULTS:Of the 36 patients assessable for efficacy,there were 2 patients(5.1%)with complete response and 16 patients(41.0%)with partial response,giving an overall response rate of 46.1%.The median progression-free survival and median overall survival for all patients were 7.1 mo(95%CI:4.6-9.7)and 12.4 mo(95%CI:9.5-15.3),respectively.Toxicities were moderate and manageable.Grade 3/4 toxicities included neutropenia(15.4%),nausea(10.3%),anemia(7.7%),thrombocytopenia(5.1%),vomiting(5.1%)and neutropenia fever(2.6%).CONCLUSION:The combination of paclitaxel and nedaplatin is active and well tolerated as a first-line therapy for patients with metastatic ESCC.
基金This article is supported by the Humanities and Social Sciences Fund of the Ministry of Education of China(17YJCZH086).
文摘With insight from the methodology of phenomenology,Jan Patocka draws multiple meanings from the special front-line experience,including new understanding of the fringe of death,absolute freedom,universal responsibility,and solidarity with enemies.The front-line experience is in sharp contrast with daily life experience,and is regarded by Patocka as a continuous consciousness of problematization toward history.This consciousness,which the front-line experience gives rise to,can be maintained through true care for reality and history.Patocka names this"care for the soul"and regards it as the core of the European spirit.The potential philosophical and historical value of the front-line experience urges Patocka to maintain an eternal fight,and he eventually concludes thatitis this eternal fight that brings forth eternal peace.
文摘损伤控制(damage control,DC)理念历经30多年的发展,其内核已实现从损伤控制外科(damage control surgery,DCS)的单纯技术概念,向损伤控制复苏(damage control resuscitation,DCR)的生理管理理念演进。纵向上,损伤控制贯穿了从受伤点急救到确定性治疗的全过程;横向上,损伤控制跨越了病理生理学、多系统外科学、介入影像学等多个学科,并可应用于平时和战时双场景,其内涵和外延的不断演进推动了损伤控制医学(damage control medicine,DCM)作为一个系统性理论体系的发展。本文系统回顾了损伤控制的发展背景、发展历程和最新进展,以战场救护中“白金十分钟”“黄金一小时”“关键三小时”时效救治作为框架,与损伤控制急救(damage control emergency,DCE)、DCR、DCS相对应,探讨构建以3D为核心的DCM理论架构,并提出我军的损伤控制体系建设参考路径。
